Jens-Erik Beck Jensen

Chief Physician

Hvidovre Hospital

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jens-Erik Beck Jensen is the Chief Physician at Hvidovre Hospital in Denmark. His research areas include metabolic syndrome, obesity, and the clinical manifestations of hypophosphatasia, as demonstrated in his recent articles. He has conducted studies on various topics, including probiotic supplementation effects, primary hyperparathyroidism, and bone health in osteoporotic patients.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (16)

Signe Torekov

Professor MSO

University of Copenhagen

DENMARK

Jens-Erik Beck Jensen

Research Interests

Contact this professor

About

Articles (10)

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation

Primary hyperparathyroidism and fracture probability

No effect of multi-strain probiotic supplementation on metabolic and inflammatory markers and newborn body composition in pregnant women with obesity: Results from a randomized, double-blind placebo-controlled study

Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study

Frailty and osteoporosis in patients with hip fractures under the age of 60—a prospective cohort of 218 individuals

The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism

Bone-microarchitecture and bone-strength in a sample of adults with hypophosphatasia and a matched reference population assessed by HR-pQCT and impact microindentation

Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study

Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals

Collaborators (16)

Signe Torekov

Rasmus Michael Sandsdal

Lise L Gluud

Felicia Cosman

Signe Schmidt

Lise Sofie Bislev

Dina Cortes

Tanja Sikjaer

Enwu Liu

Sjurdur Olsen

Lasse Gliemann

Sebastian Strøm Rönnquist

Anja Lisbeth Frederiksen

Andreas Munk Petersen

Bente Merete Stallknecht

Niklas Rye Jørgensen

Make your next move.